Feedback
Settings

Settings

Goto Application

120 results
Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC_EX:G16C* AND EN_ALLTXT:(coronavirus OR coronaviruses OR coronaviridae OR coronavirinae OR orthocoronavirus OR orthocoronaviruses OR orthocoronaviridae OR orthocoronavirinae OR betacoronavirus OR betacoronaviruses OR betacoronaviridae OR betacoronavirinae OR sarbecovirus OR sarbecoviruses OR sarbecoviridae OR sarbecovirinae OR "severe acute respiratory syndrome" OR sars OR "2019 ncov" OR covid)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 12
1.WO/2022/081920SYSTEMS FOR AND METHODS OF TREATMENT SELECTION
WO - 21.04.2022
Int.Class G01N 33/567
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
566using specific carrier or receptor proteins as ligand binding reagent
567utilising isolate of tissue or organ as binding agent
 Appl.No PCT/US2021/055096 Applicant THE REGENTS OF THE UNIVERSITY OF CALIFORNIA Inventor KROGAN, Nevan
The disclosure relates to a system comprising software that predicts responsiveness of subjects to certain disease modifying drugs. Embodiments of the disclosure include methods comprising calculating a differential interaction score (DIS), correlating the DIS with the likelihood that a dysfunctional protein-protein interaction is the causal agent of a disease or disorder, and identifying a subject responsive to a treatment based upon the causal agent.
2.202141019538IN SILICO EVALUATION AND SYNTHESIS OF NOVEL SULFONAMIDES AS PROMISING ANTI-VIRAL LEAD MOLECULES DOCKED AGAINST ANTI-COVID-19 PROTEIN TARGETS: SARS-COV-2 MAIN PROTEASE
IN - 07.05.2021
Int.Class A61K /
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
 Appl.No 202141019538 Applicant SAMPATH CHINNAM Inventor SAMPATH CHINNAM
COVID-19 pandemic has led us to design and develop novel organic molecules as medicinally promising lead molecules which can prevent the SARS-CoV-2 virus of the infected patients. The current invention provides potential anti-viral drugs docked against anti-COVID-19 protein targets: SARS-CoV-2 main protease, drug-likeness, efficacy, molecular docking, physicochemical and pharmacokinetic studies of novel synthesized sulfonamide analogues. Physicochemical and pharmacokinetic properties have been evaluated on the basis of certain parameters like Lipinski rule of 5 (RO5 rule) and ADMET (absorption, distribution, metabolism, excretion and toxicity). All the synthesized compounds follow Lipinski rule of five (RO5 rule) and the compounds followed the range of rotational bonds, hydrogen bond acceptors (HBA), hydrogen bond donors (HBD), topological surface area (TPSA), and number of violations, etc. All these compounds shown good pharmacokinetic properties, zero renal OCT2 substrate toxicity and negligible toxicity values. BOILED-egg model was carried out for evaluating the gastrointestinal absorption and brain penetration effect. Compounds 3b and 3d comes under white region of egg and exhibited good gastrointestinal absorption, whereas, 3a, 3c, 3e and 3f compounds fall under yellow region (yolk) of egg which showed good brain penetration effect. All novel sulfonamide analogues including commercially available anti-COVID-19 drugs, Hydroxychloroquine and Umifenovir docked with anti-COVID-19 protein targets, i.e., PDB: 6VWW & 6Y2E. Compound 3c when docked with PDB: 6VWW shown maximum energy of -22.06 kcal/mol with two hydrogen binding interactions which are better than marketed drugs. Similarly, compound 3a exhibited highest energy of -14.00 kcal/mol.
3.WO/2022/013781PEPTIDE EPITOPE VACCINES FOR COVID-19 AND METHOD OF DESIGNING, MAKING AND USING THE SAME
WO - 20.01.2022
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
 Appl.No PCT/IB2021/056355 Applicant UNIVERSITY OF SOUTHERN CALIFORNIA Inventor BOGDAN, Paul
Computer systems and computer implemented methods are presented for designing and making vaccines to pathogens, particular viral pathogens. Vaccine compositions for COVID-19 are also disclosed, as well as method of using the same.
4.202200591943D PHARMACOPHORE MODEL FOR THE RAPID COMPUTATIONAL SCREENING OF SARS-COV-2 MODULATORS AND COMPOSITIONS AND METHODS THEREOF
US - 24.02.2022
Int.Class G16C 20/40
GPHYSICS
16INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
CCOMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
20Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
40Searching chemical structures or physicochemical data
 Appl.No 17409433 Applicant FluoroMe, Inc., Inventor Dimitrios VLACHAKIS

The invention encompasses compositions and compounds for inhibiting CoV2 Spike GP and human ACE2 proteins and a 3D pharmacophore model described herein provides the means for rapid, high-throughput virtual screening of potential anti-CoV2 modulators thus facilitating, optimizing and speeding up the search for the discovery of a potent anti-COVID-19 agent and methods of treatment and prevention thereof.

5.202221008681INHIBITORY POTENTIAL OF RESVERATROL AND ITS NATURAL ANALOGUES AGAINST RNA DEPENDANT RNA POLYMERASE (RDRP) OF RHIZOPUS ORYZAE IN MUCORMYCOSIS THROUGH IN SILICO INVESTIGATIONS
IN - 11.03.2022
Int.Class C07K /
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
 Appl.No 202221008681 Applicant MITHUN RUDRAPAL Inventor MITHUN RUDRAPAL
Mucormycosis (or black fungus infection) is a life-threatening, but rare fungal infection with predominant occurrence in immune-suppressed patients following the SARS-CoV-2 infection/ COVID-19 illness. Rhizopus oryzae causes about 70% of all cases of mucormycosis. The present invention provides insights to in silico investigations of resveratrol and its two natural analogues, piceatannol, and 3,5,4'-trimethoxy-trans-stilbene for their development as successful antifungal agents targeting the R. O. specific RNA dependant RNA polymerase (R. O. RdRp) to combat the deadly mucormycosis. In in silico studies, molecular docking, molecular dynamics (MD) simulations, density functional theory (DFT), drug-likeness and ADMET predictions were performed. The Ramachandran plot validated the predicted structure, and the the 3D structure predicted using the homology model was of acceptable quality. The findings of docking and MD simulations revealed that the resveratrol and its two natural analogues could potentially inhibit the R. O. RdRp. The present invention proves that resveratrol and its two natural analogues are the potential inhibitors of R. O. RdRp. Resveratrol and piceatannol possess promising in silico inhibitory potential against R. oryzae RdRp based on docking, molecular dynamics and DFT studies.
6.202111010632A NOVEL DRUG FOR SARS-COV-2
IN - 28.05.2021
Int.Class G16B /
GPHYSICS
16INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
 Appl.No 202111010632 Applicant Abhay J. Gandhi Inventor Abhay J. Gandhi
COVID-19, a new strain of coronavirus (CoV), was identified in Wuhan, China, in 2019. It then extended across the globe and was termed as pandemic in 2020. Though no vaccine or drug is available to combat this disease, it is necessary to look over it through alternative sciences. Available symptoms of covid 19 was thoroughly studied and reviewed through Ayurveda classics to understand the nature of the disease into Ayurevdic perspective. Other available sources from internet, pre prints, etc. The molecular Docking were done by Pyrx Software with Autodock. The Lipinski Rule of Five data generated from Swiss ADME software and Target prediction of selected phytoconstituents were done from Swiss target prediction.In Ayurveda, it can be considered as Janapadaudhwans, vaat-kafaj sannipatik jwara, Aupsargik vyadhi and Dhatupaka awastha. In the molecular docking study the binding energy and inhibition of 6 Gingesulphonic acid from Zingiber Officinalis are greater than Hydroxychloroquine and quinine. Most of the selected phytoconstituents follow Lipinski rule of five. Target prediction of selected phytoconstituents were done on target of SARS-COV-2, humoral immunity and antiviral. Every selected phytoconstituents were work on minimum of the target.Thus, from the above results obtained from reviewing Ayurveda classics and from the results obtained after virtual screening of selected drugs we can conclude that Ayurveda drugs can have appreciable results in combating Covid 19.
7.1020220061025코로나 바이러스 감염증 치료 물질 발굴 방법 및 시스템
KR - 12.05.2022
Int.Class G16C 20/50
GPHYSICS
16INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
CCOMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
20Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
50Molecular design, e.g. of drugs
 Appl.No 1020210149449 Applicant (주)제이엘케이 Inventor 이명재
본 발명은 코로나 바이러스 감염증 치료 물질 발굴 방법 및 시스템에 관한 것으로, 본 발명에 따른 코로나 바이러스 감염증 치료 물질 발굴 방법은 데이터 구성부가 코로나 바이러스와 결합 가능한 후보로 구성되는 결합 가능 데이터를 구성하는 데이터 구성 단계; 정보 선별부가 상기 결합 가능 데이터 중에서 코로나 바이러스와 결합 가능한 비 약물들의 정보를 선별하는 선별 단계; 약물 생성부가 상기 비 약물과 유사 구조의 약물을 생성하는 약물 생성 단계; 및 약물 도출부가 상기 생성된 약물 중에서 후보 약물을 도출하는 약물 도출 단계;를 포함하여 구성된다.
8.202111002858METHOD FOR INHIBITING SARS-COV-2 THROUGH PHARMACOPHORE MODELLING OF APREMILAST
IN - 23.09.2022
Int.Class G16C /
GPHYSICS
16INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
CCOMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
 Appl.No 202111002858 Applicant Sanskriti University Inventor Dr. Vishal M. Balaramnavar
A method for inhibiting SARS-CoV-2 through Mpro inhibition using an apremilast drug, wherein the method comprising the steps: developing multiple pharmacophore models to extract features from a drug, validating the developed multiple pharmacophore models of the apremilast with one or more pre-defined models of existing coronavirus drugs, performing virtual screening of a database of drugs against the validated pharmacophore models to assign score in order to identify features of apremilast that are similar to existing coronavirus drugs, performing structure based virtual screening of the validated pharmacophore models by molecular docking, assigning a score to each of the validated pharmacophore model of the apremilast by using scoring technique in order to identify the high binding affinity and efficiency of the apremilast for coronaviruses, analyzing and comparing the score obtained from the virtual screening and the structure based virtual screening for classifying scored pharmacophore models based on molecular docking and coronaviruses.
9.202211013566COMPOUNDS INHIBITING PROTEOLYTIC ENZYMES FOR ANTI-SARS-CORONAVIRUS (SARS-COV-2) ACTIVITY
IN - 25.11.2022
Int.Class C07D /
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
 Appl.No 202211013566 Applicant Chitkara University Inventor SINGH, Manjinder
The present disclosure relates generally to pharmaceutical compounds. Specifically, the present disclosure provides a compound of Formula I for inhibition of proteolytic enzymes Furin and 3CLpro for anti-SARS-CoV-2 activity or anti-coronavirus activity. The representative compounds exhibited high binding affinity in terms of good docking score and key residue interactions with the proteases. The docked compounds were also noted to have favorable ADME properties and drug-likeness.
10.20170058430Bacterial identification in clinical infections
US - 02.03.2017
Int.Class G16B 30/00
GPHYSICS
16INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
30ICT specially adapted for sequence analysis involving nucleotides or amino acids
 Appl.No 15119745 Applicant The Arizona Board of Regents on behalf of the University of Arizona Inventor George S. Watts

Disclosed herein are methods of identifying infections, such as methods of identifying bacterial infections which utilize whole metagenome sequence analysis to sequence the entire wound microbiome of clinical samples. The disclosed methods use fast k-mer based sequence analysis, predictive modeling, and Bayesian network analysis, to analyze bacterial metagenomic sequence compositions in conjunction with clinical factors to stratify communities of bacteria into healing versus non-healing clusters. The methods of identifying infections can include performing molecular analysis of a patient wound sample, preparing the data obtained from the molecular analysis, diagnosing the wound sample and/or prognosing the wound sample. The disclosed methods can also be used to identify protein function as well as novel biomarkers.

# -